The U.S. Food and Drug Administration approved topical ruxolitinib (Opzelura), the ...

Use patterns of topical calcineurin inhibitors (TCIs) were reviewed in 8,015 ...

The COVID-19 Research Database was used to assess the risk of ...

Tralokinumab-ldrm (Adbry™) was approved in December 2021 for the treatment of ...

The efficacy and safety of abrocitinib in atopic dermatitis patients after ...

For patients with moderate-to-severe atopic dermatitis (AD), the FDA approved two ...

Do probiotic supplements improve the symptoms of atopic dermatitis (AD)? A ...

Warren R. Heymann, MD, FAAD offers his commentary on JAK inhibitors ...

One controversy over the last several decades is how hard water ...

Four members of the DermWorld Editorial Advisory Workgroup shared exciting news ...